Osteoporosis in children: Pediatric and pediatric rheumatology perspective: A review

Pediatric Rheumatology

Volumn 7, Issue , 2009, Pages 16-

  Uziel, Yosef ^a,b   Zifman, Eyal ^a,b   Hashkes, Philip J ^c  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; GLUCOCORTICOID; HEPARIN; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; BONE DENSITY; BONE DISEASE; BONE PAIN; CHILD; CLINICAL TRIAL; DERMATOMYOSITIS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGITIS; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFLAMMATORY DISEASE; JAW OSTEONECROSIS; JUVENILE RHEUMATOID ARTHRITIS; LIFESTYLE; MALAISE; MYALGIA; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PEDIATRICS; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 70449732397     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-7-16     Document Type: Review

References (65)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000, 17:1-45.
2. Gordon CM, Baim S, Bianchi ML. Special report on the 2007 Pediatric Position Development Conference of the International Society for Clinical Densitometry. South Med J 2008, 101:740-743.
3. Bishop N, Braillon P, Burnham J. Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008, 11:29-42. 10.1016/j.jocd.2007.12.004, 18442751.
4. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr 2004, 144:253-257. 10.1016/j.jpeds.2003.08.054, 14760271.
5. Hartman C, Shamir R, Eshach-Adiv O. Assessment of osteoporosis by quantitative ultrasound versus dual energy X-ray absorptiometry in children with chronic rheumatic diseases. J Rheumatol 2004, 31:981-985.
6. Prevrhal S, Fuerst T, Fan B. Quantitative ultrasound of the tibia depends on both cortical density and thickness. Osteoporos Int 2001, 12:28-34. 10.1007/s001980170154, 11305080.
7. Trimpou P, Bosaeus I, Bengtsson BA, Landin-Wilhelmsen K. High correlation between quantitative ultrasound and DXA during 7 years of follow-up. Eur J Radiol 2009,
8. Bukhari M. The National Osteoporosis Guideline Group's new guidelines: what is new?. Rheumatology (Oxford) 2009, 48:327-329. 10.1093/rheumatology/ken454, 19129351.
9. Engelke K, Libanati C, Liu Y. Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA). Bone 2009, 45:110-118. 10.1016/j.bone.2009.03.669, 19345291.
10. Akler G, Rotman-Pikielny P, Kots E. To treat or not to treat? A young girl with multiple vertebral fractures. IMAJ 2009,
11. Vega D, Maalouf NM, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92:4514-4521. 10.1210/jc.2007-0646, 17895323.
12. Faienza MF, Brunetti G, Colucci S. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab 2009, 94:2269-2276. 10.1210/jc.2008-2446, 19401376.
13. Trapani S, Civinini R, Ermini M. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 1998, 18:45-49. 10.1007/s002960050056, 9782532.
14. Lilleby V, Lien G, Frey FK. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum 2005, 52:2051-2059. 10.1002/art.21115, 15986346.
15. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 2007, 56:1966-1973. 10.1002/art.22691, 17530722.
16. Cervera R, Khamashta MA, Font J. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003, 82:299-308. 10.1097/01.md.0000091181.93122.55, 14530779.
17. Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juveile dermatomyositis: assessment using dual x-ray absorptiometry. Arthritis Rheum 2003, 48:2294-2298. 10.1002/art.11211, 12905484.
18. Aggarwal P, Aggarwal A, Gupta S, Misra R. Osteopenia is common in adult male patients with active juvenile idiopathic arthritis. J Rheumatol 2006, 33:1642-1645.
19. Okumus O, Erguven M, Deveci M. Growth and bone mineralization in patients with juvenile idiopathic arthritis. Indian J Pediatr 2008, 75:239-243. 10.1007/s12098-008-0052-3, 18376091.
20. Henderson CJ, Cawkwell GD, Specker BL. Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 1997, 40:1967-1975. 10.1002/art.1780401108, 9365085.
21. Henderson CJ, Specker BL, Sierra RI. Total-body bone mineral content in non-corticosteroid treated postpubertal females with juvenile rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum 2000, 43:531-540. 10.1002/1529-0131(200003)43:3<531::AID-ANR8>3.0.CO;2-X, 10728745.
22. De Benedetti F, Rucci N, Del Fattore A. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 3563, 54:3551-2006.
23. Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol 2001, 26:79-94. 10.1677/jme.0.0260079, 11241160.
24. Rideout CA, McKay HA, Barr SI. Self-reported lifetime physical activity and areal bone mineral density in healthy postmenopausal women: the importance of teenage activity. Calcif Tissue Int 2006, 79:214-222. 10.1007/s00223-006-0058-7, 17033722.
25. Tlacuilo-Parra A, Morales-Zambrano R, Tostado-Rabago N. Inactivity is a risk factor for low bone mineral density among haemophilic children. Br J Haematol 2008, 140:562-567. 10.1111/j.1365-2141.2007.06972.x, 18275434.
26. Ausili E, Focarelli B, Tabacco F. Bone mineral density and body composition in a myelomeningocele children population: effects of walking ability and sport activity. Eur Rev Med Pharmacol Sci 2008, 12:349-354.
27. Lien G, Selvaag AM, Flatø B. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:833-840. 10.1002/art.20963, 15751052.
28. Alwis G, Linden C, Stenevi-Lundgren S. A school-curriculum-based exercise intervention program for two years in pre-pubertal girls does not influence hip structure. Dyn Med 2008, 7:8. 10.1186/1476-5918-7-8, 2397397, 18442381.
29. Rautava E, Lehtonen-Veromaa M, Kautiainen H. The reduction of physical activity reflects on the bone mass among young females: a follow-up study of 142 adolescent girls. Osteoporos Int 2007, 18:915-922. 10.1007/s00198-006-0312-x, 17211530.
30. Chevalley T, Bonjour JP, Ferrari S, Rizzoli R. High-protein intake enhances the positive impact of physical activity on BMC in prepubertal boys. J Bone Miner Res 2008, 23:131-142. 10.1359/jbmr.070907, 17892378.
31. Greer FR, Krebs NF. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006, 117:578-585. 10.1542/peds.2005-2822, 16452385.
32. Winzenberg T, Shaw K, Fryer J, Jones G. Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. BMJ 2006, 333:775. 10.1136/bmj.38950.561400.55, 1602024, 16980314.
33. Carrasco R, Lovell DJ, Giannini EH. Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial. Arthritis Rheum 2008, 58:3932-3940. 10.1002/art.24041, 19035501.
34. Lovell DJ, Glass D, Ranz J. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. Arthritis Rheum 2006, 54:2235-2242. 10.1002/art.21956, 16802360.
35. Stark LJ, Davis AM, Janicke DM. A randomized clinical trial of dietary calcium to improve bone accretion in children with juvenile rheumatoid arthritis. J Pediatr 2006, 148:501-507. 10.1016/j.jpeds.2005.11.043, 16647414.
36. Seiquer I, Mesias M, Hoyos AM. A Mediterranean dietary style improves calcium utilization in healthy male adolescents. J Am Coll Nutr 2008, 27:454-462.
37. Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford) 2009, 48:210-212. 10.1093/rheumatology/ken394, 18930963.
38. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008, 122:1142-1152. 10.1542/peds.2008-1862, 18977996.
39. Bowden SA, Robinson RF, Carr R, Mahan JD. Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic. Pediatrics 2008, 121:e1585-e1590. 10.1542/peds.2007-2111, 18519464.
40. Marinovic D, Dorgeret S, Lescoeur B. Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study. Pediatrics 2005, 116:e102-e108. 10.1542/peds.2004-1838, 15995009.
41. Bianchi ML, Bardare M, Caraceni MP. Bone metabolism in juvenile rheumatoid arthritis. Bone Miner 1990, 9:153-162. 10.1016/0169-6009(90)90081-P, 2350617.
42. Maalouf J, Nabulsi M, Vieth R. Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children. J Clin Endocrinol Metab 2008, 93:2693-2701. 10.1210/jc.2007-2530, 2729206, 18445674.
43. Kilpinen-Loisa P, Nenonen H, Pihko H, Makitie O. High-dose vitamin D supplementation in children with cerebral palsy or neuromuscular disorder. Neuropediatrics 2007, 38:167-172. 10.1055/s-2007-990266, 18058622.
44. Misra M, Pacaud D, Petryk A. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008, 122:398-417. 10.1542/peds.2007-1894, 18676559.
45. El-Hajj FG, Nabulsi M, Tamim H. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 2006, 91:405-412. 10.1210/jc.2005-1436, 16278262.
46. Ward L, Tricco AC, Phuong P. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007, (4):CD005324.
47. Bachrach LK, Ward LM. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009, 94:400-409. 10.1210/jc.2008-1531, 19033370.
48. Poyrazoglu S, Gunoz H, Darendeliler F. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop 2008, 28:483-487.
49. Rauch F, Munns C, Land C. Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. J Bone Miner Res 2009, 24:1282-9. 10.1359/jbmr.090213, 19257821.
50. Streeten EA, McBride D, Puffenberger E. Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone 2008, 43:584-590. 10.1016/j.bone.2008.04.020, 18602879.
51. Barros ER, as da Silva MR, Kunii IS, Lazaretti-Castro M. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 2008, 21:811-818.
52. Apkon S, Coll J. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. Am J Phys Med Rehabil 2008, 87:139-143. 10.1097/PHM.0b013e3181583ddc, 17912140.
53. Inoue Y, Shimojo N, Suzuki S. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol 2008, 27:909-912. 10.1007/s10067-008-0864-6, 18330609.
54. Lethaby C, Wiernikowski J, Sala A. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. J Pediatr Hematol Oncol 2007, 29:613-616. 10.1097/MPH.0b013e318142b7a1, 17805035.
55. Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007, 356:1075-1076. 10.1056/NEJMc062792, 17347467.
56. Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004, 19:1742-1745. 10.1359/JBMR.040711, 15355570.
57. Waterhouse KM, Auron A, Srivastava T. Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol 2007, 22:282-287. 10.1007/s00467-006-0306-0, 17033813.
58. Bianchi ML, Cimaz R, Bardare M. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000, 43:1960-1966. 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J, 11014345.
59. Cimaz R, Gattorno M, Sormani MP. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002, 29:1786-1792.
60. Rudge S, Hailwood S, Horne A. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005, 44:813-818. 10.1093/rheumatology/keh538, 15695300.
61. Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 2008, 37:196-200.
62. Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk?. N Engl J Med 2006, 355:2278-2281. 10.1056/NEJMp068157, 17135582.
63. Vahle JL, Long GG, Sandusky G. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438. 10.1080/01926230490462138, 15204966.
64. Cinamon U, Turcotte RE. Primary hyperparathyroidism and malignancy: "studies by nature". Bone 2006, 39:420-423. 10.1016/j.bone.2006.01.146, 16530496.
65. Vahle JL, Zuehlke U, Schmidt A. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 2008, 23:2033-2039. 10.1359/jbmr.080807, 18684088.